Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BTCH30003 > Lecture 21 - Role of government in Biotechnology > Flashcards

Lecture 21 - Role of government in Biotechnology Flashcards

1
Q

What is the overview of the Therapeutics R&D Value Chain

A

Discovery > development > market

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the flow for Discovery in Therapeutics R&D Value Chain

A

Gene&raquo_space;(deciding where to look(academia)» Protein (target) > Screen&raquo_space;(Select commercial opportunity(academia, MNC, SME))» lead&raquo_space;(Create case for investment (MNC, SME and sometimes acedemia)» Candidate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the flow for Development in Therapeutics R&D Value Chain

A

Phase I (FTIH)&raquo_space;(early development (SME MNC))» Phase II (POC) > Phase III( Late development (MNC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the flow for market in Therapeutics R&D Value Chain

A

File&raquo_space;(commercialisation)» Launch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Health Products from a buyer’s perspective

A
  • 2 key MARKET ACCESS BARRIERS - regulatory and pricing
  • Products are often NON DISCRETIONARY
  • Products sell into highly COMPLEX markets with many STAKEHOLDERS
  • The product is IP claim and label claim
  • Leads to UNCONVENTIONAL business models
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Examples of Government support for Biotech

A
  • Education and training
  • Supporting PFROs (Publicly Funded Research Organisations)
  • Buying health products and services
  • Translation Funding (MRFF)
  • Accelerators/ incubators
  • Tax incentives
  • Advisory programmes - capability, networks, effectiveness - often offer matched funded grants
  • Regulatory policy
  • Sector Capability
  • Enhance collaboration with PFRO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the examples of Supporting PFROs (Publicly Funded Research Organisations)

A

o Universities
o CSIRO
o MRIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the examples of Research Infrastructure support

A

Expensive Kit: Synchrotron/ ANSTO
-Expensive to run
Capability (crystallography, tissue banks, GMP etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the examples for Buying health products and services

A 
o	PBS
o	MBS
o	PL
o	NDIA/ ADHA
o	Other health funds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the examples for Translation Funding (MRFF)

A

o AC
o Medical Research Future Fund: BTF, Biotech Bridge, Horizons,
o Challenge based programs Biotech Horizons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the examples for Tax incentives

A

o R&D Tax incentive for business (esp. refundable part)
o Tax incentives for Early Stage Investors
o (Philanthropy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the examples for Advisory programmes - capability, networks, effectiveness - often offer matched funded grants

A

o AusIndustry - Business Management (also IC and AC)
o Austrade
o TGA Assist
o IP Australia patent hub
o Special purpose initiatives (eg. Biotech bridge)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the examples for Regulatory policy

A

o Comp Meds and GMP
o CTN/ CTX
o Patent system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the examples for Sector Capability

A

o Clinical Trial Initiatives

o Growth Centers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the examples for Enhance collaboration with PFRO

A

o Innovation Connections
o Cooperative Research Centres and CRC-Ps
o ARC Linkage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the Top 5 Trends for Biotech

A
  1. Big data analytics
  2. Growth in use of personalised medicine
  3. Digitisation of healthcare
  4. Automation of healthcare delivery
  5. Move to value-based care
17
Q

What tiers of Value-derived compensation: move from fee-for-service to increasingly outcome-based models

A

FFS-Payment Not Linked to Quality > FFS - Payment Linked to Quality > Alternative payment Models (based on FFS architecture) > Population- based Payment

18
Q

Meaning of FFS-Payment Not Linked to Quality

A

Reimbursement is solely represented by volume of patient care, and it is not characterised by care quality or outcome

19
Q

Meaning of FFS - Payment Linked to Quality

A

% of total reimbursement is proportional to the quality of care delivery

20
Q

Meaning of Alternative payment Models (based on FFS architecture)

A
  • % of total reimbursement is linked to efficient care delivery.
  • Payment is largely based on volume but opportunities to share care-efficiency-led saving or 2-sided risk exist.
21
Q

Meaning of Population- based Payment

A

Reimbursement is not linked to yearly care volume , rather, providers are awarded for offering quality services to beneficiaries for a longer period of time(generally more than 1 year)

22
Q

What is Accountable care organizations(ACOs)

A

-An ACO is a network of providers (physicians, hospitals, etc.) that give coordinated, high quality care to Medicare beneficiaries.

23
Q

Example of value based care delivery models introduced the US in Bundled payments

A

In this model, the amount to be paid to treat a specific condition is calculated based on historical prices

24
Q

What is a bundled payment

A

an episode-based payment wherein a single payment is made for an entire episode of care which may include several procedures and different settings of care. Here, the providers are collectively reimbursed for the expected costs to treat a specific condition.

25
Q

What is the risk for bundled payment

A

If the providers provide care at a higher cost than that determined under bundled payment, they incur losses

26
Q

What is the risk in ACOs

A

Providers may have to repay Medicare if they fail to provide value-based care to Medicare beneficiaries

27
Q

What does the model tell us about ACOs

A

the providers in the network share savings if the ACO is able to deliver high-quality care in a cost-effective manner by preventing unnecessary and redundant services

28
Q

What does the model tell us about bundled payment

A

the amount to be paid to treat a specific condition is calculated based on historical prices

BTCH30003 (19 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions